Home/Pipeline/Idetrexed

Idetrexed

Ovarian Cancer

Phase 1bActive

Key Facts

Indication

Ovarian Cancer

Phase

Phase 1b

Status

Active

Company

Algok Bio

About Algok Bio

Algok Bio is a private, preclinical-stage biotech company operating as a specialized asset developer, bridging the gap between early discovery and commercialization. The company's core strategy involves in-licensing or acquiring promising therapeutic leads, particularly those ready for preclinical studies, and advancing them through development using its team's proven expertise. Its current pipeline is anchored by idetrexed, a clinical-stage folate receptor-targeted therapy for ovarian cancer, alongside earlier-stage antibody candidates. Algok Bio's model is designed to de-risk asset acquisition for larger pharma partners by providing rigorous lead identification and development execution.

View full company profile

Therapeutic Areas

Oncology

Other Ovarian Cancer Drugs

Drug	Company	Phase	Status
EXO‑Ovarian Cancer Test	INOVIQ	Phase 2/3	Active
CAR‑iNK‑OvCa	Cartherics	Preclinical	Active
MagSense™ FR Imaging Agent	Imagion Biosystems	Pre‑clinical	Active
Yondelis (trabectedin)	PharmaMar	Approved	Commercial/Lifecycle
Measovir®-based candidate	Oncovita	Pre-clinical	Preclinical activity demonstrated
NP-G2-044 + Chemotherapy Agents	Novita Pharmaceuticals	Phase 2a	Active (combination strategy)
Ivospemin (SBP-101)	Panbela Therapeutics	Phase 2	Active
Ovarian Cancer Early Detection Assay	GenEndeavor	Pre-clinical	Active
INVAC-1	Invectys	Phase 2	Active
Folate Receptor-Targeted PCC	Indi Molecular	Preclinical	Active
Immunomodulator Platform	OmniCyte	Pre-clinical	Active
Platform Candidate	FLAG Therapeutics	Preclinical	Active